<DOC>
	<DOCNO>NCT00822211</DOCNO>
	<brief_summary>The purpose study assess efficacy safety vildagliptin 50 mg bid compare placebo add-on therapy metformin Chinese patient T2DM inadequately control metformin alone .</brief_summary>
	<brief_title>Efficacy add-on Therapy With Vildagliptin Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients T2DM receive metformin least 8 week stable dose least 1500 mg daily minimum 4 week prior visit 1 Agreement maintain dose metformin randomization end study Age range 1878 year inclusive Body mass index ( BMI ) range 2040 kg/m2 inclusive Visit 1 HbA1c range &gt; 7.0 â‰¤10 % Visit 1 Agreement maintain prior diet exercise habit full course study Ability comply study requirement Fasting Plasma Glucose ( FPG ) &gt; 270 mg/dl ( 15 mmol/L ) Visit 1 Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>HbA1c reduction</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>add-on metformin</keyword>
	<keyword>Chinese patient</keyword>
</DOC>